Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Results 1 - 20 of 24 : 1 2 Next »

Recs

0
Member Avatar TerryFool (21.60) Submitted: 3/25/2014 5:50:51 AM : Outperform Start Price: $4.35 SNTA Score: -8.58

BUY@ 4.1 TP 15

Recs

0
Member Avatar TerryHoodSr (49.09) Submitted: 3/12/2014 12:06:13 PM : Outperform Start Price: $4.27 SNTA Score: -7.76

SPEC BP 4.3 TP 7.0

Recs

0
Member Avatar CountDaBean (75.27) Submitted: 2/16/2014 3:07:05 AM : Outperform Start Price: $6.32 SNTA Score: -38.38

New drug in trials. Expect shares to jump to 10.00 a share if trials are successful

Recs

0
Member Avatar diablo138 (42.30) Submitted: 1/12/2014 12:53:38 PM : Outperform Start Price: $6.50 SNTA Score: -40.38

Lot's of medicine in the pipeline, great outlook for this company!

Recs

0
Member Avatar jpokergman (< 20) Submitted: 11/18/2013 5:39:35 PM : Outperform Start Price: $4.98 SNTA Score: -24.22

big insider buy....that's why.

Recs

0
Member Avatar ptanabe (52.82) Submitted: 8/14/2013 12:36:42 PM : Outperform Start Price: $5.78 SNTA Score: -42.06

k

Recs

0
Member Avatar ssanaka (< 20) Submitted: 6/16/2013 10:19:00 AM : Outperform Start Price: $4.09 SNTA Score: -16.39

possible blockbuster lung cancer drug in the pipeline

Recs

0
Member Avatar frankyz669 (< 20) Submitted: 9/3/2010 10:23:24 AM : Outperform Start Price: $2.92 SNTA Score: -33.33

Magic Formula - though speculative. I think it made the MF list because of huge cash infusion from selling its position with another partner.

Recs

0
Member Avatar smith972 (84.60) Submitted: 4/21/2010 5:30:50 PM : Outperform Start Price: $4.04 SNTA Score: -57.30

I'll watch SNTA in caps here.

Recs

1
Member Avatar cibient (25.23) Submitted: 2/4/2010 1:14:38 PM : Outperform Start Price: $4.08 SNTA Score: -76.49

Surge of insider buying inspires confidence. While this means nothing if the drug ultimately doesn't fly, or heavy dilution tramples existing shareholders, the company has a good balance sheet due to the recent capital raise.

Recs

0
Member Avatar aulden1954 (< 20) Submitted: 1/15/2010 7:51:08 PM : Outperform Start Price: $4.84 SNTA Score: -82.02

Their product base has started rough with the cancer drug but, they have good products in the pipe line that is giving some positive light on the companies pipe line of products.

I like my chances because the company has many other products they are bringing to market. If they only bring one to market and get bough out they have become a success haven't they.

Recs

0
Member Avatar iddqkfyou (< 20) Submitted: 1/13/2010 7:37:20 AM : Outperform Start Price: $4.63 SNTA Score: -77.83

Insiders just (Jan.) purchased 5+% of the company at this price. Insiders do not buy millions of their own biotech company without good reason.

Recs

0
Member Avatar dgu004 (93.75) Submitted: 12/22/2009 5:00:32 AM : Underperform Start Price: $6.50 SNTA Score: +105.98

Went too high before the trail is successful. Red ink will show again for the quarters to come.

Recs

0
Member Avatar TuffPicks (< 20) Submitted: 9/22/2009 12:17:50 PM : Outperform Start Price: $3.15 SNTA Score: -47.73

wallstreet buy list

Recs

0
Member Avatar ChicagoBreeze (< 20) Submitted: 10/23/2008 3:41:04 PM : Outperform Start Price: $5.72 SNTA Score: -142.53

Promising risky microcap biotech for various types of cancer with phase 3 interium results later out this year. One person described this as possiblly the "next celgene". Also has high insider ownership. NO insiders have sold since it went public nearly 2 years ago.

Recs

0
Member Avatar biovestor (< 20) Submitted: 6/28/2008 6:22:16 AM : Outperform Start Price: $5.93 SNTA Score: -83.39

A cancer biotech stock with a promising Phase 3 candidate for metastatic melanoma (elesclomol) along with a full early stage pipeline.

Recs

0
Member Avatar glfraley (99.32) Submitted: 1/29/2008 3:14:44 PM : Outperform Start Price: $7.15 SNTA Score: -87.12

Just won orphan status for their already fast tracked melanoma drug. should be interesting to see how this develops.

Recs

0
Member Avatar ivhadit (< 20) Submitted: 1/19/2008 6:41:50 PM : Outperform Start Price: $6.50 SNTA Score: -91.62

IF THIS HITS WATCH OUT

Recs

0
Member Avatar Dtrifan (< 20) Submitted: 11/13/2007 9:49:01 PM : Outperform Start Price: $8.37 SNTA Score: -83.43

Cancer drug market at a low price

Recs

0
Member Avatar jcarcopo (< 20) Submitted: 10/19/2007 9:55:47 AM : Outperform Start Price: $8.11 SNTA Score: -78.89

Promising Melanoma (#1 Cancer Killer) Cancer Drug. $80M upfront from Glaxo, up to $1 Billion total for milestones. Fast R&D pipeline with several other drug canidates. Plenty of insider action at $9-$10. Stage 2 trial went well, stage 3 proceeding, FDA fast track drug candidate. $12-$14 easy within a month.

Results 1 - 20 of 24 : 1 2 Next »

Featured Broker Partners


Advertisement